Cargando…

Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes

OBJECTIVE: To investigate the efficacy, safety, and microbiology of a thermosensitive otic suspension of ciprofloxacin (OTO-201) in children with bilateral middle ear effusion undergoing tympanostomy tube placement. STUDY DESIGN: Two randomized, double-blind, sham-controlled phase 3 trials. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Albert H., White, David R., Moss, Jonathan R., Bear, Moraye, LeBel, Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971606/
https://www.ncbi.nlm.nih.gov/pubmed/27188702
http://dx.doi.org/10.1177/0194599816645526
_version_ 1782446131253346304
author Park, Albert H.
White, David R.
Moss, Jonathan R.
Bear, Moraye
LeBel, Carl
author_facet Park, Albert H.
White, David R.
Moss, Jonathan R.
Bear, Moraye
LeBel, Carl
author_sort Park, Albert H.
collection PubMed
description OBJECTIVE: To investigate the efficacy, safety, and microbiology of a thermosensitive otic suspension of ciprofloxacin (OTO-201) in children with bilateral middle ear effusion undergoing tympanostomy tube placement. STUDY DESIGN: Two randomized, double-blind, sham-controlled phase 3 trials. Patients were randomized to intratympanic OTO-201 or sham. SETTING: Children with bilateral middle ear effusion undergoing tympanostomy tube placement. SUBJECTS/METHODS: Studies evaluated 532 patients (6 months to 17 years old) in a combined analysis of efficacy (treatment failure: presence of otorrhea, otic or systemic antibiotic use, lost to follow-up, missed visits), safety (audiometry, otoscopy, tympanometry), and microbiology. RESULTS: There was a lower cumulative proportion of treatment failures in patients receiving OTO-201 vs tympanostomy tubes alone (1) on days 4, 8, 15, and 29; (2) on day 15, primary end point (23.0% vs 45.1%; age-adjusted odds ratio, 0.341; P < .001; reduction in relative risk, 49%); and (3) on day 15, blinded-assessor otorrhea treatment failure (7.0% vs 19.4%; age-adjusted odds ratio, 0.303; P < .001; reduction in relative risk, 64%). Per-protocol and subgroup analyses (baseline demographics, pathogen type, culture status, effusion type, microbiologic response) supported these findings. There were no drug-related serious adverse events; the most frequent treatment-emergent adverse events in both groups were pyrexia, postoperative pain, nasopharyngitis, cough, and upper respiratory tract infection. OTO-201 administration had no evidence of increased tube occlusion and no negative effect on audiometry, tympanometry, or otoscopy. CONCLUSIONS: Combined analysis of 2 phase 3 trials demonstrated a lower cumulative proportion of treatment failures through day 15 compared with TT alone when OTO-201 was administered intratympanically for otitis media with bilateral middle ear effusion at time of tympanostomy tube placement.
format Online
Article
Text
id pubmed-4971606
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-49716062016-08-15 Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes Park, Albert H. White, David R. Moss, Jonathan R. Bear, Moraye LeBel, Carl Otolaryngol Head Neck Surg Pediatric Otolaryngology OBJECTIVE: To investigate the efficacy, safety, and microbiology of a thermosensitive otic suspension of ciprofloxacin (OTO-201) in children with bilateral middle ear effusion undergoing tympanostomy tube placement. STUDY DESIGN: Two randomized, double-blind, sham-controlled phase 3 trials. Patients were randomized to intratympanic OTO-201 or sham. SETTING: Children with bilateral middle ear effusion undergoing tympanostomy tube placement. SUBJECTS/METHODS: Studies evaluated 532 patients (6 months to 17 years old) in a combined analysis of efficacy (treatment failure: presence of otorrhea, otic or systemic antibiotic use, lost to follow-up, missed visits), safety (audiometry, otoscopy, tympanometry), and microbiology. RESULTS: There was a lower cumulative proportion of treatment failures in patients receiving OTO-201 vs tympanostomy tubes alone (1) on days 4, 8, 15, and 29; (2) on day 15, primary end point (23.0% vs 45.1%; age-adjusted odds ratio, 0.341; P < .001; reduction in relative risk, 49%); and (3) on day 15, blinded-assessor otorrhea treatment failure (7.0% vs 19.4%; age-adjusted odds ratio, 0.303; P < .001; reduction in relative risk, 64%). Per-protocol and subgroup analyses (baseline demographics, pathogen type, culture status, effusion type, microbiologic response) supported these findings. There were no drug-related serious adverse events; the most frequent treatment-emergent adverse events in both groups were pyrexia, postoperative pain, nasopharyngitis, cough, and upper respiratory tract infection. OTO-201 administration had no evidence of increased tube occlusion and no negative effect on audiometry, tympanometry, or otoscopy. CONCLUSIONS: Combined analysis of 2 phase 3 trials demonstrated a lower cumulative proportion of treatment failures through day 15 compared with TT alone when OTO-201 was administered intratympanically for otitis media with bilateral middle ear effusion at time of tympanostomy tube placement. SAGE Publications 2016-05-17 2016-08 /pmc/articles/PMC4971606/ /pubmed/27188702 http://dx.doi.org/10.1177/0194599816645526 Text en © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Pediatric Otolaryngology
Park, Albert H.
White, David R.
Moss, Jonathan R.
Bear, Moraye
LeBel, Carl
Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes
title Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes
title_full Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes
title_fullStr Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes
title_full_unstemmed Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes
title_short Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes
title_sort phase 3 trials of thermosensitive ciprofloxacin gel for middle ear effusion in children with tubes
topic Pediatric Otolaryngology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971606/
https://www.ncbi.nlm.nih.gov/pubmed/27188702
http://dx.doi.org/10.1177/0194599816645526
work_keys_str_mv AT parkalberth phase3trialsofthermosensitiveciprofloxacingelformiddleeareffusioninchildrenwithtubes
AT whitedavidr phase3trialsofthermosensitiveciprofloxacingelformiddleeareffusioninchildrenwithtubes
AT mossjonathanr phase3trialsofthermosensitiveciprofloxacingelformiddleeareffusioninchildrenwithtubes
AT bearmoraye phase3trialsofthermosensitiveciprofloxacingelformiddleeareffusioninchildrenwithtubes
AT lebelcarl phase3trialsofthermosensitiveciprofloxacingelformiddleeareffusioninchildrenwithtubes